2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatmentCharacteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder
Fuehrlein B, Ralevski E, O'Brien E, Jane JS, Arias AJ, Petrakis IL. Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. Addictive Behaviors 2013, 39: 374-378. PMID: 24090619, DOI: 10.1016/j.addbeh.2013.08.026.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic alpha-AntagonistsAdultAgedAlcohol DrinkingAlcoholismComorbidityConnecticutDiagnosis, Dual (Psychiatry)FemaleHumansMaleMassachusettsMecamylamineMental DisordersMiddle AgedNicotinic AntagonistsPlacebosPrazosinPsychotropic DrugsSeverity of Illness IndexStress Disorders, Post-TraumaticSubstance-Related DisordersTreatment OutcomeVeteransYoung AdultConceptsPost-traumatic stress disorderCo-occurring illnessesAlcohol dependenceStress disorderCo-occurring alcohol dependenceDetailed drinking historiesDifferent treatment studiesMajor depressive episodeClinical treatment settingsHeavy drinking daysAlcohol use disorderPre-treatment characteristicsBaseline characteristicsDepressive episodePsychiatric symptomsUse disordersDrinking daysDomains of psychopathologyTreatment settingsDrinking historyTreatment studiesPsychopathological domainsPTSD groupPTSD symptomsMore days
2011
Effects of Acamprosate on Cognition in a Treatment Study of Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O'Brien E, Jane JS, Dean E, Dwan R, Petrakis I. Effects of Acamprosate on Cognition in a Treatment Study of Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. The Journal Of Nervous And Mental Disease 2011, 199: 499-505. PMID: 21716064, DOI: 10.1097/nmd.0b013e3182214297.Peer-Reviewed Original ResearchConceptsCognitive functioningSchizophrenia spectrum disordersSpectrum disorderAlcohol dependenceComorbid alcohol dependencePsychotic symptomsSymptoms of psychosisCognitionEffects of acamprosateAlcohol useFunctioningTreatment studiesAlcohol reductionMemorySample of patientsAcamprosate treatmentGroup of patientsNegative effectsAlcohol consumptionDisordersAttentionSymptomsAcamprosatePatientsSchizophreniaTreatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O’Brien E, Jane JS, Dwan R, Dean E, Edens E, Arnaout B, Keegan K, Drew S, Petrakis I. Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2011, 7: 64-73. PMID: 26954912, DOI: 10.1080/15504263.2011.569440.Peer-Reviewed Original ResearchEfficacy of acamprosateAlcohol dependenceSchizophrenia spectrum disordersMedication treatmentComorbid schizophreniaSignificant group x time interactionGroup x time interactionComorbid alcohol dependenceAlcohol use disorderSymptoms of schizophreniaX time interactionAcamprosate groupComorbid conditionsTreatment trialsAbstinent patientsClinical trialsSpectrum disorderAcamprosateGeneral populationUse disordersPatientsSchizoaffective disorderPositive symptomsSchizophrenic symptomsConsecutive days